The single-use bioreactor market is expected to be one of the fastest-growing segments in the bioprocessing industry over the next few years. This is due to the increasing demand for biopharmaceuticals and biologic products, as well as the cost and time savings associated with single-use systems. Additionally, the increasing adoption of single-use technologies, such as single-use bioreactors, is expected to drive the growth of the market. Companies are focusing on the development of next-generation bioreactors that can improve process efficiency, reduce costs, and increase production capacity. In addition, key players are focusing on increasing the automation of bioreactors to reduce labor costs and increase process control.
Single-Use Bioreactors Market in terms of revenue was estimated to be worth $4.2 billion in 2023 and is poised to reach $10.0 billion by 2028, growing at a CAGR of 19.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as the increasing adoption of single-use bioreactors among startups and SMEs, lower operational complexity of single-use bioreactors compared to conventional stainless-steel bioreactors, reduced energy and water consumption, growing size of the biologics and biosimilars market, and technological advancements in single-use bioreactors.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=49113750
Browse in-depth TOC on “Single-Use Bioreactors Market”
408 – Tables
48 – Figures
345 – Pages
The monoclonal antibodies segment accounted for the largest share of the type of molecule segment in the single-use bioreactors market in 2022.
Based on the type of molecule, the global single-use bioreactors market is segmented into monoclonal antibodies (mAbs), vaccines, gene-modified cells, stem cells, and other molecules. The monoclonal antibodies segment accounted for the largest share of the global single-use bioreactors market in 2022 owing to increasing demand for single-use bioreactors in the manufacturing of mAbs, and factors such as low investment costs and a reduction in time-intensive changeover procedures.
The mammalian cells segment accounted for the fastest growing share of the type of cell segment in the single-use bioreactors market in 2022.
Based on the type of cell, the global single-use bioreactors market is segmented into mammalian cells, bacterial cells, yeast cells, and other cells. In 2022, the mammalian cells segment accounted for the largest share of the market owing to increasing adoption of mammalian cells due to their post-translational modification capacity and human protein-like molecular structure assembly are expected to propel market growth.
The Asia Pacific region is the fastest-growing region of the single-use bioreactors market in 2022.
Based on the region, the single-use bioreactors market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to register the highest CAGR during the forecast period. Factors such as the growing biopharmaceutical industry, rising investments by pharmaceutical & biotechnology companies, and the growing number of CROs & CMOs in several Asia Pacific countries are supporting the growth of the market in the region.
Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=49113750
Single-Use Bioreactors Market Dynamics:
Drivers:
- Increasing adoption of SUBs among small companies and startups
- Reduced automation complexity
- Ease in the cultivation of marine organisms
- Reduced energy and water consumption
- Growing biologics market
- Technological advancements in SUBs
- Increasing biopharmaceutical R&D
Restraints:
- Regulatory concerns related to SUBs
- Issues related to leachables and extractables
Opportunities:
- Patent expiry
- Emerging markets
Challenges:
- Need for improved single-use sensors
- Standardization of single-use designs
Key Market Players:
Key players in the single-use bioreactors Market are Sartorius AG (Germany), Thermo Fisher Scientific (US), Danaher Corporation (US), and Merck Millipore (Germany).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=49113750
Recent Developments:
- In November 2022, Sartorius GA (Germany) planned to invest in growing its operations by establishing new R&D laboratories and digitalizing & automating equipment, among other approaches. This development was aimed at meeting the high demand from the biopharmaceutical industry.
- In November 2022, Danaher Corporation (US) subsidiary, Cytiva invested around USD 8 million to expand its Fast Trak center in Shanghai, China. The Single-use Technologies (SUT) center of excellence in Asia offers new product R&D tests and validation with an aim to facilitate the industry’s application of SUT throughout the region.
- In August 2022, Thermo Fisher Scientific (US) opened its largest single-use technology manufacturing site in Greater Nashville with an investment of USD 105 million to meet the growing demand for the bioprocessing materials needed to produce vaccines and breakthrough therapies for cancer and other diseases.
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/single-use-bioreactor-market-49113750.html